{{Rsnum
|rsid=16840493
|Chromosome=1
|position=240704176
|Orientation=plus
|GMAF=0.1143
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 92.9 | 7.1 | 0.0
| HCB | 81.0 | 18.2 | 0.7
| JPT | 71.7 | 25.7 | 2.7
| YRI | 68.0 | 29.3 | 2.7
| ASW | 75.4 | 22.8 | 1.8
| CHB | 81.0 | 18.2 | 0.7
| CHD | 68.8 | 31.2 | 0.0
| GIH | 89.1 | 10.9 | 0.0
| LWK | 58.2 | 39.1 | 2.7
| MEX | 62.1 | 37.9 | 0.0
| MKK | 63.5 | 34.6 | 1.9
| TSI | 92.2 | 6.9 | 1.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs16840493
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: T, MAF= 0.08, combined P value= 5.74E-05.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470176
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs16840493
|overall_frequency_n=17
|overall_frequency_d=128
|overall_frequency=0.132812
|n_genomes=13
|n_genomes_annotated=0
|n_haplomes=15
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}